Gefitinib (Iressa®) and Erlotinib (Tarceva®) are first-line selective inhibitors of EGFR TK domain (Tyrosine Kinase Inhibitors, TKI), and are effective in NSCLC population of patients [16, 17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.